Protocol Ledger

NCT05074420 · Phase III · TERMINATED

A Study of Baricitinib (LY3009104) in Children With COVID-19

Interventional Phase III clinical trial protocol NCT05074420 sponsored by Eli Lilly and Company in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-21 Enrollment: 6 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05074420
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)6 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05074420
Protocol FieldVerified Registry Value
NCT IdentifierNCT05074420
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment6 participants (ACTUAL)
Registered Start Date2021-12-21
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05074420
Hospital Research SiteLocationSite Profile
University Hospitals Cleveland Medical CenterCleveland, OHOpen Hospital Dossier ->
Hospital de Clinicas de Porto AlegrePorto Alegre, BrazilOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI